Acta Scientific Ophthalmology (ASOP)

Case Report Volume 3 Issue 3

Thyroid Eye Disease (Ted) Management: A Case Report

Bashir Alnajjar*

Ophthalmology, Surger, Seha Abodhabi, UAE

*Corresponding Author: Bashir Alnajjar,Ophthalmology, Surger, Seha Abodhabi, UAE.

Received: January 31, 2020; Published: February 27, 2020

×

  Thyroid eye disease (TED) is seen most commonly with Graves’ disease Symptoms include diplopia, eyelid erythema and retraction, and soreness and grittiness of eyes with increased watering. Severe cases (3 - 5%) may present with pain, corneal ulceration, optic nerve compression and partial/total loss of vision.

  Corticosteroids are the primary treatment for active phase TED, although there is risk of adverse effects such as weight gain, hypertension and immunosuppression with long-term, high-dose use.

  We will discuss a patient history with TED before, during and after treatment with tocilizumab and steroids Tocilizumab is current treatment options for moderate-to-severe.

  Given the role in the pathogenesis of TED of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory is that inhibition of IL-6 by tocilizumab may be an effective treatment in TED by directly reducing the inflammatory response.

Keywords: Thyroid; Eye Disease

×

References

  1. The  European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the  (2016).
  2. Graves’ ophthalmopathy. N Engl J Med
  3. publication/41562276_Graves'_ophthalmopathy_N_Engl_J_-Med-Clinical Response to -Tocilizumab in Severe Thyroid Eye Disease
  4. publication/303893349_Clinical_Response_to_Tocilizumab_in_Severe_Thyroid_Eye_Disease

 

×

Citation

Citation: Bashir Alnajjar. “Thyroid Eye Disease (Ted) Management: A Case Report”. Acta Scientific Ophthalmology 3.2 (2020): 40-44.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US